Prosecution Insights
Prosecution Insights
57 pending office actions • 33 art units • 55 examiners • 0 of 57 (0%) have an AI response strategy ready • 41 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 28 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 28 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 5 (9%) |
| §103 only | 13 (23%) |
| §102 only | 5 (9%) |
| §112 only | 8 (14%) |
| Double-patenting only | 2 (4%) |
| Double-patenting + other | 5 (9%) |
| Multi-statute (no §101) | 18 (32%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FOLEY, SHANON A | 2 | 73.2% | +18.0% |
| BELL, SARA ELIZABETH | 2 | 69.1% | +38.2% |
| LEE, SIN J | 1 | 68.9% | +25.5% |
| KIM, SAMUEL CHONG | 1 | 48.3% | +70.1% |
| VAJDA, KRISTIN ANN | 1 | 84.0% | +10.9% |
| MPAMUGO, CHINYERE | 1 | 27.6% | +27.5% |
| ELENISTE, PIERRE PAUL | 1 | 36.5% | +32.1% |
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| SODERQUIST, ARLEN | 1 | 59.8% | +26.5% |
| KARUNASENA, ENUSHA | 1 | 0.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548622 | Methods of Treatment with Selective CB2 Receptor Agonists | BELL, SARA ELIZABETH | 60d overdue |
| 17431462 | Methods for purifying bacterial polysaccharides | CREWS, JARET JAMES | 53d overdue |
| 18019379 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | RODRIGUEZ, RAYNA B | 35d overdue |
| 18322395 | PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT | HAMA, JOANNE | 17d overdue |
| 18565626 | METHODS OF TREATMENT | VALENROD, YEVGENY | 17d overdue |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | CHEN, STACY BROWN | 8d overdue |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | TSAY, MARSHA M | 2d overdue |
| 18024245 | STREAMLINED ASSAY PREPARATION | YOUNG, NATASHA E | 1d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18548622 | Methods of Treatment with Selective CB2 Receptor Agonists | BELL, SARA ELIZABETH | 60d overdue |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 8d |
| 18825795 | AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | LEE, SIN J | — |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | — |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | — |
| 18722084 | DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES | MPAMUGO, CHINYERE | — |
| 18713747 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | ELENISTE, PIERRE PAUL | — |
| 18699159 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | FOLEY, SHANON A | — |
| Art Unit | Apps |
|---|---|
| 1624 | 4 |
| 1622 | 4 |
| 1645 | 3 |
| 1674 | 2 |
| 1625 | 2 |
| 1671 | 2 |
| 1626 | 2 |
| 1656 | 2 |
| 1631 | 2 |
| 1628 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18825795 | AQUEOUS FORMULATION COMPRISING 1-(4-{[4-(DIMETHYLAMINO)PIPERIDIN-1-YL]CARBONYL}PHENYL)-3-[4-(4,6-DIMORPHOLIN-4-YL-1,3,5-TRIAZIN-2-YL)PHENYL]UREA | LEE, SIN J | — | §103DP | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18842257 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR RESPIRATORY CONDITION MONITORING AND CARE | KIM, SAMUEL CHONG | — | §101§103§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18789272 | SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | VAJDA, KRISTIN ANN | 1624 | DP | Non-Final OA | — | Pending | Jul 30, 2024 |
| 18722084 | DIGITAL MEDICINE COMPANION FOR TREATING AND MANAGING SKIN DISEASES | MPAMUGO, CHINYERE | 3685 | §101§103 | Non-Final OA | — | Pending | Jun 20, 2024 |
| 18713747 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | ELENISTE, PIERRE PAUL | — | §112 | Non-Final OA | — | Pending | May 28, 2024 |
| 18706732 | METHODS OF TREATING MITOCHONDRIAL MYOPATHIES USING ANTI-GDF15 ANTIBODIES | ABBAS, SYED JARAR | 1674 | §103§112DP | Non-Final OA | — | Pending | May 01, 2024 |
| 18699159 | IMMUNOGENIC LNP COMPOSITIONS AND METHODS THEREOF | FOLEY, SHANON A | — | §102§103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18249752 | METHODS FOR MEASURING DYSTROPHIN IN TISSUE SAMPLES | SODERQUIST, ARLEN | — | §103 | Non-Final OA | — | Pending | Feb 28, 2024 |
| 18586896 | CETYLTRIMETHYLAMMONIUM BROMIDE (CTAB) AS A LYSIS AND FLOCCULATION REAGENT IN GENE THERAPY DOWNSTREAM PROCESSES | KARUNASENA, ENUSHA | — | §103 | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18442988 | BTLA Fusion Protein Agonists and Uses Thereof | BUNNER, BRIDGET E | — | §102§103§112DP | Non-Final OA | — | Pending | Feb 15, 2024 |
| 18532424 | Papain-like protease (PLpro) inhibitors | BELL, SARA ELIZABETH | 1625 | §102 | Non-Final OA | — | Pending | Dec 07, 2023 |
| 18521196 | CLAUDIN 18.2 TARGETING CHIMERIC ANTIGEN RECEPTORS AND BINDING AGENTS AND USES THEREOF | BELYAVSKYI, MICHAIL A | — | DP | Non-Final OA | — | Pending | Nov 28, 2023 |
| 18562387 | RECOMBINANT EXPRESSION OF KLEBSIELLA PNEUMONIAE O-ANTIGENS IN ESCHERICHIA COLI | GANGLE, BRIAN J | 1645 | §102§112 | Non-Final OA | 43d | Pending | Nov 20, 2023 |
| 18557987 | VACCINATION AGAINST BACTERIAL AND BETACORONAVIRUS INFECTIONS | FOLEY, SHANON A | 1671 | §103§112 | Non-Final OA | 8d | Pending | Oct 30, 2023 |
| 18488191 | COMPOUND FOR THE TREATMENT OF CANCER | KLINKEL, KORTNEY L | 1627 | §112 | Non-Final OA | 56d overdue | Pending | Oct 17, 2023 |
| 18555058 | COMBINATION THERAPY COMPRISING A PKC INHIBITOR AND A MEK INHIBITOR | O DELL, DAVID K | 1621 | §103 | Non-Final OA | 5d | Pending | Oct 12, 2023 |
| 18552453 | Ether-Linked Antiviral Compounds | ANDERSON, REBECCA L | 1626 | §112 | Non-Final OA | 71d overdue | Pending | Sep 26, 2023 |
| 18551038 | PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | VIVLEMORE, TRACY ANN | 1638 | §102§103§112Other | Non-Final OA | 9d | Pending | Sep 18, 2023 |
| 18550326 | Methods For Treatment of Vitiligo | FERGUSON, JALISA HOLMES | 1626 | §102§103§112 | Non-Final OA | — | Pending | Sep 13, 2023 |
| 18549158 | Treatment of Breast Cancer with Amcenestrant and Palbociclib | LEESER, ERICH A | 1622 | §103 | Non-Final OA | 22d | Pending | Sep 05, 2023 |
| 18459381 | CELL CULTURE PROCESS | NGUYEN, NGHI V | 1653 | §103 | Non-Final OA | 14d | Pending | Aug 31, 2023 |
| 18275634 | Methods of Protecting RNA | MCKILLOP, JOHN CHARLES | 1637 | §101§102§103 | Non-Final OA | 15d | Pending | Aug 03, 2023 |
| 18347698 | SELF-AMPLIFYING RNA ENCODING AN INFLUENZA VIRUS ANTIGEN | CHEN, STACY BROWN | 1672 | §103§112 | Final Rejection | 8d overdue | Pending | Jul 06, 2023 |
| 18343968 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF | DEVI, SARVAMANGALA | 1645 | — | Final Rejection | — | Pending | Jun 29, 2023 |
| 18268959 | SOLID FORMS OF A CDK2 INHIBITOR | MCDOWELL, BRIAN E | 1624 | §112 | Non-Final OA | — | Pending | Jun 21, 2023 |
| 18258027 | IMPROVED PHARMACEUTICAL COMPOSITIONS CONTAINING ADENO-ASSOCIATED VIRAL VECTOR | RIGA, MICHAEL ANGELO | 1634 | §102§103§112 | Non-Final OA | — | Pending | Jun 16, 2023 |
| 18335259 | IL-12 Variants and Uses Thereof | GODDARD, LAURA B | 1642 | §102§103§112 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 18257215 | HILIC UPLC-MS Method For Separating and Analyzing Intact Adeno-Associated Virus Capsid Proteins | LY, KRISTINA ELISABETH | 1671 | §103§112 | Non-Final OA | — | Pending | Jun 13, 2023 |
| 18255869 | METHODS AND COMPOSITIONS FOR INHIBITING EXCESS NUCLEIC ACID PRECIPITATION | TSAY, MARSHA M | 1656 | §101§102§103 | Non-Final OA | 2d overdue | Pending | Jun 04, 2023 |
| 18322395 | PURIFICATION OF ANTIBODY DRUG CONJUGATES USING A SODIUM PHOSPHATE GRADIENT | HAMA, JOANNE | 1647 | §103§112Other | Non-Final OA | 17d overdue | Pending | May 23, 2023 |
| 18252124 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | OGUNBIYI, OLUWATOSIN A | 1645 | §102Other | Non-Final OA | 13d | Pending | May 08, 2023 |
| 18250570 | CRYSTAL-FREE HIGH-CONCENTRATION TESTOSTERONE CYPIONATE FORMULATIONS | MITCHELL, EDWIN COLEMAN | 1619 | §103 | Final Rejection | 26d overdue | Pending | Apr 26, 2023 |
| 18249581 | PEG-FREE AQUEOUS SUSPENSIONS FOR PARENTERAL ADMINISTRATION OF A CORTICOSTEROID | AGGARWAL, SAHIL CHANDER | 1623 | §103 | Non-Final OA | — | Pending | Apr 19, 2023 |
| 18024245 | STREAMLINED ASSAY PREPARATION | YOUNG, NATASHA E | 1774 | §103§112 | Non-Final OA | 1d overdue | Pending | Mar 01, 2023 |
| 18042561 | GROUP B STREPTOCOCCUS POLYSACCHARIDE-PROTEIN CONJUGATES, METHODS FOR PRODUCING CONJUGATES, IMMUNOGENIC COMPOSITIONS COMPRISING CONJUGATES, AND USES THEREOF | JACKSON-TONGUE, LAKIA J | 1600 | §102 | Final Rejection | — | Pending | Feb 22, 2023 |
| 18041447 | Methods of Protecting RNA | BATES, KEENAN ALEXANDER | 1631 | §112 | Final Rejection | — | Pending | Feb 13, 2023 |
| 18004109 | Preparation Of A Pyrimidinyl-3,8-Diazabicyclo[3.2.1]Octanylmethanone Derivative And Salt Thereof | MOORE, SUSANNA | 1624 | §102Other | Non-Final OA | 36d overdue | Pending | Jan 03, 2023 |
| 18146014 | COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND A DNA-PK INHIBITOR FOR THE TREATMENT OF CANCER | JOHANSEN, PETER N. | 1644 | §103DP | Non-Final OA | 85d overdue | Pending | Dec 23, 2022 |
| 18002555 | COMPUTERIZED DECISION SUPPORT TOOL AND MEDICAL DEVICE FOR SCRATCH DETECTION AND FLARE PREDICTION | WESTFALL, SARAH ANN | 3791 | §103 | Non-Final OA | — | Pending | Dec 20, 2022 |
| 18002368 | METHOD OF TREATMENT OF INFLAMMATORY BOWEL DISEASE USING ANTI-TL1A ANTIBODIES | KAUFMAN, CLAIRE M | 1674 | §103§112 | Non-Final OA | — | Pending | Dec 19, 2022 |
| 17799992 | PURIFICATION OF SACCHARIDES | LAU, JONATHAN S | 1693 | §102§103 | Final Rejection | — | Pending | Aug 16, 2022 |
| 17607341 | REAL-TIME TRACKING AND MANAGEMENT OF STANDARD WORKFLOWS | KONERU, SUJAY | 3624 | §101§103 | Non-Final OA | — | Pending | Oct 28, 2021 |
| 17431462 | Methods for purifying bacterial polysaccharides | CREWS, JARET JAMES | 1691 | §103§112Other | Final Rejection | 53d overdue | Pending | Aug 17, 2021 |
| 17299180 | Cells with reduced inhibitor production and methods of use thereof | SPANGLER, JOSEPH RANKIN | 1656 | §103 | Final Rejection | — | Pending | Jun 02, 2021 |
| 17278866 | SSI CELLS WITH PREDICTABLE AND STABLE TRANSGENE EXPRESSION AND METHODS OF FORMATION | LEONARD, ARTHUR S | 1631 | §103§112 | Non-Final OA | — | Pending | Mar 23, 2021 |
| 16978354 | ANTI-PD-1 ANTIBODY COMPOSITIONS | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | 30d overdue | Pending | Sep 04, 2020 |
| 16486363 | MULTI-SITE SPECIFIC INTEGRATION CELLS FOR DIFFICULT TO EXPRESS PROTEINS | SINGH, ANOOP KUMAR | 1632 | §112Other | Non-Final OA | — | Pending | Aug 15, 2019 |
| 18841455 | NOVEL S1P1 RECEPTOR AGONIST, CRYSTALLINE SALTS, PROCESSES FOR PREPARING, AND USES RELATED THERETO | AULAKH, CHARANJIT | — | §112 | Non-Final OA | — | Pending | Aug 26, 2024 |
| 18566862 | Administration of a Compound to Individuals with Hepatic Impairment | TRAN, ERIC | 1629 | §103Other | Non-Final OA | 12d | Pending | Dec 04, 2023 |
| 18524124 | METHODS OF TREAMENT | INAM, SAHAR | 1622 | §103 | Final Rejection | 30d overdue | Pending | Nov 30, 2023 |
| 18565626 | METHODS OF TREATMENT | VALENROD, YEVGENY | 1628 | §103§112 | Non-Final OA | 17d overdue | Pending | Nov 30, 2023 |
| 18548622 | Methods of Treatment with Selective CB2 Receptor Agonists | BELL, SARA ELIZABETH | 1625 | §102§103Other | Non-Final OA | 60d overdue | Pending | Sep 01, 2023 |
| 18259843 | Methods of Treatment | ABDALHAMEED, MANAHIL MIRGHANI ALI | 1622 | §103DPOther | Non-Final OA | 71d | Pending | Jun 29, 2023 |
| 18249774 | ISOXAZOLE DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERED RELATED THERETO | BRAUN, MADELINE E | 1624 | §112 | Non-Final OA | 29d | Pending | Apr 20, 2023 |
| 18019379 | UREA DERIVATIVES AS PYRUVATE KINASE ACTIVATORS | RODRIGUEZ, RAYNA B | 1628 | §102§112 | Non-Final OA | 35d overdue | Pending | Feb 02, 2023 |
| 17777909 | METHODS OF ADMINISTERING VOXELOTOR | SANCHEZ, JUSTIN CHRISTOPHER | 1622 | §102 | Final Rejection | 29d | Pending | May 18, 2022 |
| 17787454 | SURFACE MODIFYING COATING FOR MEDICAL DEVICES | VASISTH, VISHAL V | 1771 | §103 | Final Rejection | 19d | Pending | Jun 20, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial